Multiple endocrine neoplasia (MEN) is characterized by the occurrence of tumours involving two or more endocrine glands; two major forms, referred to as MEN1 and MEN2, are recognized. MEN1 is characterized by parathyroid, pancreatic islet and anterior pituitary tumours, whilst MEN2 is characterized by medullary thyroid carcinoma (MTC) in association with phaeochromocytoma. There are three clinical variants, referred to as MEN2A, MEN2B and MTC-only. All these forms of MEN may be inherited as autosomal dominant syndromes. The MEN1 gene is on chromosome 11q13 and about 300 MEN1 mutations have been identified. These are of diverse types and are scattered throughout the coding region. There is also a lack of genotype-phenotype correlation. All these findings make it difficult to implement MEN1 mutational analysis in the clinical setting. The situation in MEN2 is more straightforward. The gene causing all three MEN2 variants is located on chromosome 10cen-10q11.2, and is the c-ret proto-oncogene which encodes a tyrosine kinase receptor with cadherin-like and cysteine-rich extracellular domains, and a tyrosine kinase intracellular domain. Specific mutations of c-ret have been identified for each of the three MEN2 variants and mutational analysis has been used in the diagnosis and management of patients and families with the MEN2 variants.

Thakker RV: Multiple endocrine neoplasia type 1; in DeGroot LJ, Jameson JL (eds): Endocrinology, ed 4. Philadelphia, Saunders, 2001, pp 2503–2517.
Marx SJ: Multiple endocrine neoplasia type 1; in Vogelstein B, Kinzler KW (eds): Genetic Basis of Human Cancer. New York, McGraw Hill, 1998, pp 489–506.
Thakker RV: Multiple endocrine neoplasia – syndromes of the twentieth century. J Clin Endocrinol Metab 1998;83:2617–2620.
Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O’Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV: Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quart J Med 1996;89:653–669.
Teh BT, Zedenius J, Kytola S, Skogseid B, Trotter J, Choplin H, Twigg S, Farnebo F, Giraud S, Cameron D, Robinson B, Calendar A, Larsson C, Salmela P: Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 1998;228:99–105.
Skogseid B, Larsson C, Lindgren PG, Kvanta E, Rastad J, Theodorsson E, Wide L, Wilander E, Oberg K: Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1992;75:76–81.
Vortmeyer AO, Böni R, Pak E, Pack S, Zhuang Z: Multiple endocrine neoplasia 1 alterations in MEN1-associated and sporadic lipomas. J Natl Cancer Inst 1998;90:398.
Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M: Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997;133:853–861.
Knudson AG: Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914–10921
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi S-E, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404–407.
The European Consortium on MEN1: Identification of the Multiple Endocrine Neoplasia type 1 (MEN1) gene. Hum Mol Genet 1997;6:1177–1183.
Pannett AAJ, Thakker RVT: Multiple endocrine neoplasia type 1 (MEN1) gene. Endocr Relat Cancer 1999;6:449–473.
Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL: Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999;84:730–735.
Gagel RF: Multiple endocrine neoplasia type 2; in DeGroot LJ, Jameson JL (eds): Endocrinology, ed 4. Philadelphia, Saunders, 2001, pp 2518–2532.
Raue F, Frank-Raue K, Graver A: Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinol Metab Clin North Am 1994;23(1):137–156.
Eng C: The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung disease. N Engl J Med 1996;335:943–951.
Thakker RV: Multiple endocrine neoplasia; in Goltzman D (ed): Metabolic Basis of Common Inherited Diseases. Philadelphia, Saunders, in press.
Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, et al: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331 (13):828–835.
Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, et al: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220(3):237–247; discussion 247–250.
You do not currently have access to this content.